Sino Biopharmaceutical Ltd. subsidiary Chia Tai-Tianqing Pharmaceutical Group Co. Ltd. has acquired greater China rights to lanifibranor from Inventiva SA in a deal worth up to $307 million.
Shares of Lava Therapeutics NV rocketed by more than 90% Sept. 26 as the company disclosed a licensing deal with Seagen Inc. to develop and commercialize preclinical-stage EGFR-targeting bispecific candidate LAVA-1223, which comes with $50 million in up-front funding and up to a potential $650 million in milestones. It also adds further validation for harnessing gamma-delta T cells to treat cancer, an approach that is growing increasingly popular.
Sino Biopharmaceutical Ltd. subsidiary Chia Tai-Tianqing Pharmaceutical Group Co. Ltd. has acquired greater China rights to lanifibranor from Inventiva SA in a deal worth up to $307 million. Included in the deal are rights to develop and commercialize the drug in mainland China, Hong Kong, Macao, and Taiwan for the treatment of nonalcoholic steatohepatitis (NASH) and other metabolic diseases.
Spero Therapeutics Inc. has come out swinging after a U.S. FDA rejection for its oral antibiotic, tebipenem Hbr, picking up a potential $600 million licensing deal with pharma giant GSK plc after agreeing on a plan with the regulator to revive the drug.
Merck KGaA has struck a collaboration and option-to-license deal with Nerviano Medical Sciences Srl centered around NMS-293, a next-generation PARP-1 inhibitor already in early clinical development for brain tumors. Merck is making a play for the poly (ADP-ribose) polymerase (PARP) inhibitor market, first opened up in December 2014 by Astrazeneca plc, when Lynparza (olaparib) was first approved in advanced ovarian cancer, going on to become a blockbuster through a partnership with Merck & Co Inc.
About four months after starting its search for strategic alternatives, Sesen Bio Inc. disclosed an all-stock merger with privately held cell-therapy specialist Carisma Therapeutics Inc., a move that sent shares (NASDAQ:SESN) down 22 cents, or 32.7%, to close at 45 cents. Sesen stockholders are expected to own about 41.7% of the combined firm, and Carisma the remainder.
Abpro Corp. and Celltrion Healthcare Inc. entered a global partnership valued at up to $1.75 billion involving ABP-102, a bispecific antibody targeting HER2-positive cancers, a move Abpro CEO Ian Chan said would help “accelerate this type of therapy for patients in need.” With ABP-102 in preclinical development, Abpro decided to start looking for a partner. HER2 is “one of the biggest targets in biotech, mostly relevant for breast, colorectal and gastric cancers,” Chan told BioWorld. “Celltrion happened to have a lot of experience in the space.”
Shares of Renovacor Inc. (NYSE:RCOR) closed at $2.18, up 28 cents, or 14.7%, on word that Rocket Pharmaceuticals Inc. is acquiring the firm in an all-stock transaction valued at $53 million. Rocket, of Cranbury, N.J., said “compelling” preclinical data generated by Cambridge, Mass.-based Renovacor validates an AAV-based transgene replacement strategy for BLC2 athanogene 3 dilated cardiomyopathy.
Basilea Pharmaceutica Ltd., having advanced a first-in-class cancer drug through preclinical studies, is selling some rights and sublicensing others for the dual-kinase inhibitor to Sillajen Inc.
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics Ltd. have launched Radiopharm Ventures LLC, a joint venture (JV) that will develop radiopharmaceutical therapies for cancer. Radiopharm Theranostics owns 51% of shares in the new entity, while MD Anderson owns 49%.